New developments in contraceptive drugs for use by women

Expert Opinion on Investigational Drugs

Volumn 11, Issue 9, 2002, Pages 1239-1251

  Glasier, Anna ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antihormones; Contraception; Oestrogen; Progestogen; Women

Indexed keywords

ANTIGESTAGEN; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ELCOMETRINE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETONOGESTREL; GENE PRODUCT; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NANDROLONE; NEW DRUG; NOMEGESTROL ACETATE; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE ANTAGONIST; STEROID HORMONE; STI 435; TRIMEGESTONE; UNCLASSIFIED DRUG;

ABORTION; ACNE; AMENORRHEA; CONTRACEPTION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; FEMALE; HUMAN; IMMUNOCONTRACEPTION; MOUSE; NONHUMAN; RAT; REPRODUCTION; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; VAGINITIS;

ANIMALS; CONTRACEPTIVE AGENTS, FEMALE; DRUG DELIVERY SYSTEMS; FEMALE; GONADAL STEROID HORMONES; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036739715     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.9.1239     Document Type: Review

References (82)

1. Quinacrine sterilization: The imperative need for american clinical trials
2. Two-year clinical efficacy trial with dose variations of a vas deferens injectable contraceptive for the male
3. Contraceptives of the future
4. The control of fertility
5. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol
6. Shorter hormone free interval in combined oral contraceptives decreases follicular development
7. Open, multi-centre comparison of efficacy cycle control and tolerability of a 23-day oral contraceptive regimen with 20 mg ethinyl estradiol and 75 mg gestodene and a 21-day regimen with 20 mg ethinyl estradiol and 150 mg desogestrel
8. The safety and contraceptive efficacy of a 24-day low dose oral contraceptive regimen containing gestodene 60 μg and ethinyloestradiol 15 μg
9. A 12-month clinical investigation with a 24-day regimen containing 15μg ethinyloestradiol plus 60μg gestodene with respect to haemostasis and cycle control
10. An open-label, multicentre, noncomparative safety and efficacy study of Mircette TM, a low-dose estroen-progestin oral contraceptive
11. Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl estradiol and 150 μg desogestrel: Effects of low estrogen doses during the hormone-free interval
12. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status and contraceptive use and hormone replacement therapy use
13. Acceptability of an oral contraceptive that reduces frequency of menstruation: The tricycle pill regime
14. Menstrual reduction with extended use of combined oral contraceptive pills: Randomized controlled trial
15. Menstruation: Choosing whether.......and when
16. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated dose of ethinyl estradiol
17. Third Generation Oral Contraceptives
18. Nestorone®: A progestin with a unique pharmacological profile
19. Drospirenone a novel progestogen with antimineralocorticoid and anti androgenic activity
20. Drospirenone - A new progestogen with antimineralocorticoid activity, resembling natural progesterone
21. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel
22. Risk of venous thromboembolisin with cyproterone or levonorgestrel contraceptives
23. Progestogens in hormone replacement therapy, new molecules, risks and benefits
24. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary function in women
25. In vitro chracterization of trimegestone : A new potent and selective progestin
26. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 μg daily
27. Implantable contraceptives for women
28. Progestin implants for female contraception
29. A multicentre efficacy and safety study of the single contraceptive implant Implanon
30. Clinical trial with Nestorone subdermal contraceptive implants
31. Recent developments in contraceptive implants at the Population Council
32. Contraceptive efficacy and clinical performance of Nestorone implants in post partum women
33. Multicentre clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate
34. Pharmacokinetics of etonorgestrel and ethinylestradiol released from a combined contraceptive vaginal ring
35. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonorgestrel and ethinyloestradiol
36. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol
37. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl oestradiol
38. Evaluation of four different contraceptive vaginal rings: Steroid serum levels, luteal activity, bleeding control and lipid profiles
39. Ovarian function during use of vaginal rings delivering three difference doses of Nestorone®
40. A multicentred Phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: Contraceptive efficacy and side effects
41. Comparative safety, efficacy and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive estradiol triphasic)
42. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch versus an oral contraceptive. A randomized controlled trial
43. Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: A pilot study
44. Treatment of primary and secondary dysmenorrhoea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: A pilot study
45. The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual loss: A double-blind dose-finding placebo-controlled study
46. Antiprogestins: The political chemistry of RU486
47. Comparison of mifepristone and high dose oestrogen-progestogen for emergency post coital contraception
48. Comparison of the Yuzpe regime, danazol and mifepristone in oral post-coital contraception
49. Comparison of three single doses of mifepristone as emergency contraception: A randomised trial
50. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle
51. Inhibition of ovulation by low-dose mifepristone (RU486)
52. Effect of daily low dose mifepristone on the ovarian cycle and on the dynamics of follicle growth
53. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days
54. Effects of long-term low-dose mifepristone on reproductive function in women
55. Effect of low daily doses of mifepristone on ovarian function and endometrial development
56. Contraceptive efficacy of daily administration of 0.5 mg mifepristone
57. Antiprogestins: Mechanism of action and contraceptive potential
58. Effect of once weekly administration of mifepristone on ovarian function in women
59. Effect of low weekly doses of mifepristone on ovarian function and endometrial development
60. Contraceptive efficacy of low doses of mifepristone
61. Feasibility of administering mifepristone as a once a month contraceptive pill
62. Early Luteal phase treatment with mifepristone (RU 486) for fertility regulation
63. Non-compliance among a group of women using a novel method of contraception
64. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin
65. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception
66. Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation
67. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters
68. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women
69. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel
70. Pharmacology of two new very selective antiprogestagens: Org 31710 and Org 31806
71. Single monthly administration of the and-progestagen Org 31710 in users of the 75 μg desogestrel progestagen-only pill: Effects on pituitary ovarian activity
72. Safety and luteal phase effects of the antiprogestin CDB - 2914 in normally cycling women
73. A single mid-follicular dose of CDB - 2914, a new antiprogestin inhibits folliculogenesis and endometrium in normally cycling women
74. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium
75. Gonadotrophin-releasing hormone-receptor antagonists
76. Pharmacokinetics of centchroman in healthy female subjects after oral administration
77. New Products: Centchroman
78. Development of an immunocontraceptive vaccine. Current status
79. Fertility regulating and immunotherapeutic vaccines reaching human trials stage
80. Regain of fertility and normality of progeny born during below protective threshold anti-body titres in women immunized with the HSD-hCG vaccine
81. Contraceptive technology and the state of science: New Horizons
82. Science, Medicine and the future; Contraception